You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Therapy Areas
4 November 2026 - Biotechnology company Pentixapharm Holding AG (Frankfurt Prime Standard: PTP) on Wednesday reported further progress towards its pivotal Phase 3 PANDA study, with US ethics approval secured and no concerns raised by the US Food and ...
4 November 2026 - ABIONYX Pharma (Euronext Paris:ABNX), a biopharma company focused on breakthrough biotherapies to address life-threatening conditions with no effective treatments, announced on Wednesday that it has signed a strategic partnership wi...
4 November 2026 - Chinese biopharmaceutical company CStone Pharmaceuticals (HKEX:2616) announced on Tuesday that it has entered into a clinical collaboration agreement with US-based Kimia Therapeutics Inc, a biopharmaceutical company developing innov...
3 November 2026 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Tuesday that it has initiated ENHANCE-3, a Phase 3 clinical trial evaluating Ohtuvayre (ensifentrine) for preventing chron...
3 November 2026 - Swedish oncology-focused development company Vivesto AB (STO:VIVE) said on Tuesday that it has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for Cantrixil as a treatment for acute myeloid leuk...
3 November 2026 - Clinical-stage biotech company Lytix Biopharma ASA (Euronext Growth Oslo:LYTIX) announced on Tuesday that its Phase II NeoLIPA study evaluating ruxotemitide in combination with pembrolizumab in patients with resectable melanoma has ...
3 November 2026 - Swedish healthcare group Asker Healthcare Group AB (STO: ASKER), which provides medical products and solutions across Europe, said on Tuesday it has acquired 100% of the shares in Teresa OÜ, an Estonian supplier of mobility aid...